Haworth HallThe KU Genome Sequencing Core, located in Haworth Hall on the KU-Lawrence campus, is equipped with the
Illumina HiSeq 2500 Next-Gen Sequencer.

The Genome Sequencing Core lab is part of the Center for Molecular Analysis of Disease Pathways, an NIH-funded Center for Biomedical Research Excellence infrastructural grant.

Next generation sequencing (NGS) is an enabling technology that is revolutionizing most aspects of biological and biomedical research, allowing whole genome analysis, transcriptomics, and epigenomics.

The mission of the Genome Sequencing Core includes the following:

1.  Provide seamless access to state-of-the-art next-generation sequencing capabilities to researchers and projects at the Center for Molecular Analysis of Disease Pathways, KU and the region, such that genomic techniques can be enabled and become part of the experimental repertoire in labs at KU and the region.

2.  Provide education, advice, lab training, and assistance to researchers in designing experiments involving NGS, as well as assistance in data handling and new method development.

3.  Serve as a catalyst for interaction and coordination with other genomics research resources at KU-Lawrence and the region to build a strong foundation for KU genomics research in the area.


Please acknowledge the Core in your publications. Doing so will ensure that we can serve you better in future.

Kindly add the following statement to your Acknowledgments:

"Research reported in this [publication] was made possible in part by the services of the KU Genome Sequencing Core.  This lab is supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under award number P20GM103638."

CMADP Events

Special seminar by Dr. Kevin W. Plaxco
Professor of Chemistry & Biochemistry
UC Santa Barbara

Wednesday, April 19, 2017 at 4:00pm
School of Pharmacy, Room 3020

"Counting molecules, dodging blood cells: real-time molecular measurements directly in the living body"
The development of technology capable of continuously tracking the levels of drugs, metabolites, and biomarkers in situ in the body would revolutionize our understanding of health and our ability to detect and treat disease. It would, for example, provide clinicians with a real-time window into organ function and would enable therapies guided by patient-specific, real-time pharmacokinetics, opening a new dimension in personalized medicine. In response my group has pioneered the development of a “biology-inspired” electrochemical approach to monitoring specific molecules that supports real-time measurements of arbitrary molecular targets (irrespective of their chemical reactivity) directly in awake, fully ambulatory subjects.
KU Today